“NAD+ treatment” can describe a small injection administered under a prescribed plan or an intravenous infusion delivered over time. Those experiences differ, but convenience and time in a chair are only part of the comparison.
The more important questions are whether the evidence matches the route, how the preparation is made, and who assesses and responds to medical concerns. Neither a faster visit nor a more elaborate setup proves greater benefit.
THE USEFUL DISTINCTION
A route comparison should include evidence and safety, not just speed, convenience, or price per session.
Read the intervention line first
The often-cited 2019 IV pilot involved eight NAD+ recipients and three saline controls. It followed plasma and urine metabolites over a short observation period. That is informative about the measured metabolic changes, but it is not a trial demonstrating long-term improvements in energy, cognition, or lifespan.
It also does not test a home subcutaneous injection program. The evidence explorer shows how a study’s actual question can be narrower than the claims surrounding it.
Sterility is part of the product
Both injections and infusions raise sterile-preparation questions. FDA has warned about unsuitable food-grade NAD+ ingredients being used for sterile drugs and has described adverse-event reports after NAD+ injectable products. The alert is not a finding about every provider, but it is a material part of informed research.
Ask for the dispensing pharmacy and the exact preparation. Our safety guide explains why an ingredient certificate or a statement about natural biology is not the same as assurance about a finished sterile medication.
Evidence: FDA: suitable ingredients for sterile compounding / FDA: compounding and approval
Find out who is responsible
For an infusion, ask who assesses you, who administers it, what monitoring is available, and how an acute reaction is managed. For a prescribed home product, ask who provides training, prescription-specific instructions, follow-up, and help with a questionable shipment or symptom.
A review site should not supply a universal injection schedule or infusion rate. Your actual clinician and pharmacist need to address the actual prescription. Confirm clinician authority and pharmacy service for your location before treating an online offer as available care.
Evidence: HHS: telehealth licensing / FDA: BeSafeRx
Compare the commitment honestly
A clinic session and a shipped prescription may have different charges for evaluation, supplies, administration, monitoring, and follow-up. Ask what is included and how renewals work. Our cost explainer helps organize those questions.
The CoreAge review and AgelessRx review describe advertised online injection offers. They do not certify that a home injection is clinically equivalent to an IV service or that either route is appropriate for you.
Evidence: CoreAge Rx: NAD+ injectable product page / AgelessRx: NAD+ injections
Open the source material
- Grant et al.: 2019 IV NAD+ metabolome pilot
Eight NAD+ recipients and three saline controls; short-term metabolite measurements, not a longevity or clinical efficacy trial.
- FDA: suitable ingredients for sterile compounding
Specific NAD+ safety communication: food-grade material, contamination risk and reported adverse events.
- FDA: compounding and approval
Compounded drugs are not FDA-approved; ingredient evidence does not certify the finished preparation.
- HHS: telehealth licensing
General licensure guidance. Individual state availability must be checked directly.
- FDA: BeSafeRx
Online pharmacy checks, not certification of a particular brand.
- CoreAge Rx: NAD+ injectable product page
Commercial description and starting price checked September 23, 2026. Benefit claims are not independent efficacy evidence.
- AgelessRx: NAD+ injections
Advertised $79 first month on a three-month plan billed in full, then $149 per month. Confirm final terms; surveys are not controlled trials.
